From: Biomolecular condensates: insights into early and late steps of the HIV-1 replication cycle
Dataset (number of proteins) | PONDR® VSL2 analysis | CH-CDF analysis | ||||||
---|---|---|---|---|---|---|---|---|
Mostly ordereda | Moderately disorderedb | Mostly disorderedc | Highly disorderedd | Q1 | Q2 | Q3 | Q4 | |
Whole proteome (20,317) | 83(0.4%) 1030(5.1%) | 6841(33.7%) 4267(21.0%) | 8095(39.8%) | 7381(36.3%) | 12,014 (59.1%) | 5177 (25.5%) | 2501 (12.3%) | 625 (3.1%) |
All human interactors (4792) | 1(0.02%) 143(2.98%) | 1828(38.1%) 1082(22.6%) | 1738(36.3%) | 1534(32.0%) | 2945 (61.4%) | 1149 (24.0%) | 612 (12.8%) | 86 (1.8%) |
Capsid interactors (252) | 0(0.0%) 12(4.7%) | 98(38.9%) 68(27.0%) | 74(29.4%) | 65(25.8%) | 180 (71.4%) | 49 (19.5%) | 21 (8.3%) | 2 (0.8%) |
GagPol interactors (221) | 0(0.0%) 6(2.7%) | 99(44.8%) 32(14.5%) | 84(38.0%) | 75(33.9%) | 122 (55.2%) | 35 (15.8%) | 59 (22.7%) | 5 (2.3%) |
Integrase interactors (210) | 0(0.0%) 8(3.8%) | 95(45.2%) 50(23.8%) | 57(27.2%) | 54(25.7%) | 143 (68.1%) | 37 (17.6%) | 28 (13.3%) | 2 (1.0%) |
Pr44Gag interactors (657) | 0(0.0%) 20(3.0%) | 264(40.2%) 126(19.2%) | 247(37.6%) | 226(34.4%) | 374 (56.9%) | 140 (21.3%) | 130 (19.8%) | 13 (2.0%) |
RT Interactors (106) | 0(0.0%) 2(1.9%) | 58(54.7%) 21(19.8%) | 25(23.6%) | 21(19.8%) | 78 (73.6%) | 19 (17.9%) | 9 (8.5%) | 0 (0.0%) |
Tat Interactors (1667) | 0(0.0%) 42(2.5%) | 617(37.0%) 420(25.2%) | 588(35.3%) | 508(30.5%) | 1034 (62.0%) | 380 (22.8%) | 234 (14.0%) | 19 (1.2%) |
Vpr interactors (657) | 0(0.0%) 19(2.9%) | 272(41.4%) 166(25.3%) | 200(30.4%) | 173(26.3%) | 432 (65.8%) | 140 (21.3%) | 73 (11.1%) | 12 (1.8%) |